SynthesisFrontiers in oncology2023
Prognostic significance of lactate dehydrogenase and its impact on the outcomes of gastric cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy.Clinical and translational medicine · 2026Review
- Prognostic value of the preoperative lactate dehydrogenase-to-albumin ratio in patients with gastrointestinal cancer.Oncology letters · 2026Article
- Model-informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records.British journal of clinical pharmacology · 2026Article
- Is the Lactate/Albumin Ratio Associated with 28-Day Mortality in Critically Ill Patients That Underwent Open Gastric Cancer Surgery? A Retrospective Single-Center Study.Journal of clinical medicine · 2026Article
- Lactate Dehydrogenase-Derived Indices and Prognosis in Patients with Resectable Gastric Cancer.JMA journal · 2026Article
- A Real-Time Online Nomogram Integrating Systemic Inflammatory Response Index and Lactate Dehydrogenase to Predict Pathological Response in Gastric Cancer Patients Receiving Neoadjuvant Chemoimmunotherapy.Cancer management and research · 2026Article
- Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study.Journal of personalized medicine · 2025Article
- U-shaped association of serum lactate dehydrogenase with all-cause mortality in cancer patients: a retrospective cohort study.BMC cancer · 2025Article
- Development and validation of a nomogram model for predicting overall survival in patients with gastric carcinoma.World journal of gastrointestinal oncology · 2025Article
- Association between lactate dehydrogenase levels and all-cause mortality in ICU patients with heart failure: a retrospective analysis of the MIMIC-IV database.BMC cardiovascular disorders · 2025Article
- Gustave Roussy Immune Score (GRImScore) as a Novel Prognostic Index for Stage III Gastric Cancer Patients: A Real-World Retrospective Study.International journal of general medicine · 2025Article
- Research Progress on the Regulation of Glycolysis in Gastric Cancer: Key Genes and Enzymes.International journal of general medicine · 2025Review
- Construction and interpretation of machine learning-based prognostic models for survival prediction among intestinal-type and diffuse-type gastric cancer patients.World journal of surgical oncology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic significance of lactate dehydrogenase (LDH) and its impact on the outcomes of gastric cancer (GC) is still unclear. We assessed the link between the levels of LDH and the overall survival (OS) and disease-free survival (DFS) in GC patients. Methods: A comprehensive search (both electronic and manual) was carried out in PubMed Results: Eighteen studies with 5328 patients were included in our review. The overall pooled HR for OS was 1.48 (95% CI: 1.22-1.80) with high heterogeneity (I2 = 86%). Subgroup analyses showed that the link between LDH and OS was more prominent in Caucasian (HR 1.50 95% CI [0.80, 2.81], p=0.21) than in Asian cohorts (HR, 1.51 95% CI [1.21, 1.87], p=0.002). No significant overall association between LDH and OS (HR = 1.12, 95% CI: 0.76-1.65, p = 0.58) was found. Similar subgroup analyses results were reported for the association between LDH and DFS. Conclusion: In patients with GC, elevated LDH levels may correlate with worse OS and DFS, but the association is not significant. LDH is a significant predictor of OS but not of DFS. Further studies with larger sample sizes and more standardized criteria for defining elevated LDH levels are needed to confirm our findings. Systematic review registration: https://www.crd.york.ac.uk/prospero, identifier CRD42023412449.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.